Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $27.63 USD
Change Today +0.52 / 1.92%
Volume 671.5K
MDCO On Other Exchanges
As of 5:20 PM 05/27/15 All times are local (Market data is delayed by at least 15 minutes).

medicines company (MDCO) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/20/15 - $32.44
52 Week Low
10/14/14 - $19.92
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MEDICINES COMPANY (MDCO)

medicines company (MDCO) Related Businessweek News

No Related Businessweek News Found

medicines company (MDCO) Details

The Medicines Company provides medicines for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for use in patients undergoing percutaneous coronary intervention; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; Minocin IV, an antibiotic for the treatment of infections due to gram-negative bacteria; Orbactiv for the treatment of acute bacterial skin and skin structure infections; PreveLeak, a mechanical vascular and surgical sealant; ready-to-use formulation of Argatroban for the treatment of thrombosis; and Recothrom, a human recombinant thrombin used as an aid to hemostasis, as well as acute care generic products for acute cardiovascular, surgery and perioperative care, and serious infectious diseases. Its development stage products include Cangrelor for the prevention of platelet activation and aggregation; IONSYS for the short-term management of acute postoperative pain; Raplixa, a dry powder topical formulation of fibrogen and thrombin; and RPX-602 for the treatment of bacterial infections. The company’s products under development also comprise ABP-700, an intravenous anesthetic agent for moderate or deep sedation and general anesthesia in patients undergoing diagnostic or therapeutic procedures; LN-PCSsc for the treatment of hypercholesterolemia; Carbavance, an antibiotic agent for the treatment of hospitalized patients with bacterial infections; and MDCO-216, a novel biologic product to reverse atherosclerotic plaque development and reduce the risk of ischemic events in patients with ACS. It has collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize ALN-PCSsc. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.

727 Employees
Last Reported Date: 03/2/15
Founded in 1996

medicines company (MDCO) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $874.6K
President, Chief Financial Officer, Treasurer...
Total Annual Compensation: $642.6K
Chief Accounting Officer and Senior Vice Pres...
Total Annual Compensation: $393.8K
Compensation as of Fiscal Year 2014.

medicines company (MDCO) Key Developments

The Medicines Company Presents Results of Phase 1 Study for MDCO-216

The Medicines Company presented the results of a Phase 1 study for MDCO-216 that showed that the drug had a significant remodeling effect on HDL particles, which correlated with increased ABCA1-mediated cholesterol efflux. This mechanism of HDL remodeling and increased cholesterol efflux may drive the removal of deposited cholesterol from vessel walls to reduce plaque burden in patients with atherosclerotic disease. The findings were presented at the 17th International Symposium on Atherosclerosis, May 23-26, in Amsterdam, The Netherlands. MDCO-216 is a complex of dimeric recombinant apolipoprotein A-1 Milano (ApoA-1 Milano) and a phospholipid (POPC) which was developed in an attempt to mimic pre-beta HDL and induce cholesterol efflux, the first step in reverse cholesterol transport, causing removal of cholesterol from the artery walls. A single infusion of MDCO-216 was shown to produce a rapid increase in ABCA1 mediated efflux, a potential marker of reverse cholesterol transport, and a marked increase in pre-beta 1 HDL. This was followed by and correlated with a decrease in smaller HDL particles and an increase in larger HDL particles which suggests significant and rapid HDL remodeling. This data provides a hypothesis for the mechanism by which MDCO-216 as a single infusion may increase the physiological process of reverse cholesterol transport and potentially reduce atherosclerotic plaque burden. In other presentations at the conference of the Phase 1 data for MDCO-216, investigators compared the pharmacokinetics and pharmacodynamics of MDCO-216 in healthy volunteers (HV’s) and CAD patients. MDCO-216 was found to profoundly stimulate the first step of reverse cholesterol transport at clinically achievable and well tolerated doses with similar PK profiles in both HV’s and coronary artery disease (CAD) patients, but with higher potency in terms of ABCA1 efflux in CAD patients. In a separate presentation, investigators assessed the safety of newly manufactured MDCO-216 in HV’s and CAD patients. MDCO-216 was shown to be well tolerated with no serious events and no significant adverse safety findings. The most common adverse events were headache and fatigue. No dose dependent effect on any safety parameter was noted, including inflammatory markers, and there were no differences in safety parameters between HV’s and CAD patients. MDCO-216, an investigational product not approved for commercial use in any market, is a complex of dimeric recombinant apolipoprotein A-1 Milano (ApoA-1 Milano) and a phospholipid (POPC) and is currently under development to improve cardiovascular outcomes by reducing plaque burden in patients with atherosclerotic disease. MDCO-216 mimics pre-beta HDL and induces cholesterol efflux, which is the first step in the reverse cholesterol transport, a process of removal of deposited cholesterol from vessel walls and therefore has a potential to reduce plaque burden in patients with CAD.

The Medicines Company Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 10:00 AM

The Medicines Company Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 10:00 AM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Glenn P. Sblendorio, President, Chief Financial Officer, Treasurer and Director.

The Medicines Company Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

The Medicines Company announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported net revenue of $126,516,000 against $177,235,000 a year ago. Loss from operations was $11,704,000 against income from operations of $14,751,000 a year ago. Income before income taxes was $10,783,000 against $17,090,000 a year ago. Net income attributable to company was $5,034,000 or $0.08 basic and diluted per share against net loss attributable to company of $4,996,000 or $0.08 basic and diluted per share a year ago. Net income attributable to company adjusted was $5,676,000 or $0.08 diluted per share against $22,109,000 or $0.33 diluted per share a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDCO:US $27.63 USD +0.52

MDCO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BTG PLC 728.00 GBp +4.50
Integra LifeSciences Holdings Corp $67.68 USD +0.93
Krka dd Novo mesto €68.00 EUR 0.00
Richter Gedeon Nyrt 4,640 +100.00
Skyepharma PLC 290.00 GBp -5.00
View Industry Companies

Industry Analysis


Industry Average

Valuation MDCO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.6x
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDICINES COMPANY, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at